Skip to main content
OpenTrials

Clinical trial condition

Anemia, Hemolytic

Explore clinical trials studying Anemia, Hemolytic. Study availability and eligibility vary by location and protocol.

1,383 public trials 239 recruiting studies
Refine in advanced search Browse all conditions

Anemia, Hemolytic trial results

Completed

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

NCT03264989

Conditions
Anemia, Anemia, Hemolytic, Anemia, Hemolytic, Congenital, +9 more
Locations
  • Novartis Investigative Site Orange, Florida, United States
  • Novartis Investigative Site Tampa, Florida, United States
  • Childrens Healthcare of Atlanta . Atlanta, Georgia, United States
  • Augusta University Georgia Patient Treatment Augusta, Georgia, United States
View Trial Details
Completed

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

NCT04053764

Conditions
Albuminuria, Anemia, Anemia, Hemolytic, +24 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • University of Illinois Hospital and Health Sciences System . Chicago, Illinois, United States
  • Our Lady of the Lake Regional Medic . Baton Rouge, Louisiana, United States
  • East Carolina University BrodySchool of Med 3 Greenville, North Carolina, United States
View all 24 locations
View Trial Details
Completed

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

NCT04820530

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Novartis Investigative Site Beijing, China
  • Novartis Investigative Site Tianjin, China
  • Novartis Investigative Site Tianjin, China
  • Novartis Investigative Site Paris, France
View Trial Details
Completed

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

NCT04558918

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • City Of Hope National Med Center City of Hope Medical Center Duarte, California, United States
  • Univ Cali Irvine ALS Neuromuscular Orange, California, United States
  • Augusta University Georgia Patient Treatment Augusta, Georgia, United States
  • Levine Cancer Insitute Carolinas Healthcare System Charlotte, North Carolina, United States
View all 39 locations
View Trial Details
Completed

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

NCT03748823

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Liverpool, Australia
  • Research Site Parkville, Australia
  • Research Site Vienna, Austria
View all 51 locations
View Trial Details
Completed

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

NCT05098028

Conditions
Anemia, Anemia, Hemolytic, Anemia, Hemolytic, Congenital, +7 more
Locations
  • Bausch Site 105 Orange, California, United States
  • Bausch Site 103 Denver, Colorado, United States
  • Bausch Site 104 Atlanta, Georgia, United States
  • Bausch Site 101 Syracuse, New York, United States
View Trial Details
Completed

LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)

NCT03593395

Conditions
Anemia, Anemia, Hemolytic, Anemia, Hemolytic, Congenital, +7 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of South Alabama Health System Mobile, Alabama, United States
  • University of Miami Miami, Florida, United States
  • Johns Hopkins All Children's Hospital St. Petersburg, Florida, United States
View all 14 locations
View Trial Details

Related conditions